Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic

Status Completed

Clinical Trial Summary

The current study aims to assess the feasibility, acceptance and clinical outcomes of a practical high-dose LFR protocol, including tapering treatments and symptom-based relapse prevention treatments, in patients with bipolar depression previously responsive to ECT and patients needing urgent treatment due to symptom severity during the COVID-19 pandemic.

Clinical Trial Description

Treatment resistant bipolar depression is a leading cause of disability and socioeconomic burden of disease, and current treatment options all suffer from critical deficiencies of efficacy, capacity, or tolerability, especially given the current COVID-19 pandemic. rTMS and aLFR in particular has the potential to overcome many of these deficiencies, and is safe and well-tolerated. Taken together with the reported findings of other groups, aLFR may be feasible, tolerable, and capable of achieving comparable and potentially better remission rates than longer 20 to 30-day courses and it may also be beneficial to taper treatments and use symptom-based relapse prevention treatments in an aLFR protocol. Importantly, our pilot data in two patients previously responsive to ECT and data from the Cole et al. study suggest that accelerated rTMS may be a potential substitute for ECT as it may be possible to achieve remission in patients with severe depressive symptoms who would otherwise receive ECT. Furthermore, there is a burden of being able to provide care to as many people as possible based on severity of illness during the pandemic. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04427137
Study type	Interventional
Source	Centre for Addiction and Mental Health
Contact
Status	Completed
Phase	N/A
Start date	June 9, 2020
Completion date	November 9, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03256162` - Ketamine as an Adjunctive Therapy for Major Depression	Phase 1
Recruiting	`NCT03396744` - Bright Light Therapy in the Treatment of Non-seasonal Bipolar Depression	Phase 1/Phase 2
Completed	`NCT01914393` - Pediatric Open-Label Extension Study	Phase 3
Active, not recruiting	`NCT03641300` - Efficacy of Convulsive Therapies for Bipolar Depression	N/A
Completed	`NCT02363738` - 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression	Phase 2
Terminated	`NCT01807741` - Asenapine for Bipolar Depression	Phase 2
Recruiting	`NCT01213121` - Neurophysiologic Changes in Patients With Bipolar Depression	Phase 4
Completed	`NCT01919892` - Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium	Phase 4
Completed	`NCT00762268` - A Trial of SAMe for Treatment-Resistant Bipolar Depression	N/A
Terminated	`NCT00566111` - Ceftriaxone in the Management of Bipolar Depression	N/A
Terminated	`NCT00217217` - Low Field Magnetic Stimulation Treatment for Bipolar Depression	Phase 3
Recruiting	`NCT04998773` - Efficacy and Biomarkers of Response of TBS in Treatment Resistant Depression	N/A
Recruiting	`NCT04939649` - Ketamine as an Adjunctive Therapy for Major Depression (2)	Phase 3
Completed	`NCT03658824` - Behavioural Activation for Bipolar Depression: A Case Series	N/A
Suspended	`NCT03674671` - Ketamine Versus Electroconvulsive Therapy in Depression	Phase 3
Recruiting	`NCT05340686` - Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression	N/A
Recruiting	`NCT05296356` - OSU6162 in Bipolar Depression (OBID)	Phase 2
Recruiting	`NCT03711019` - Efficacy of Convulsive Therapies During Continuation	N/A
Completed	`NCT02088580` - Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients	N/A
Terminated	`NCT00272025` - Treatment Resistant Bipolar Depression	Phase 1